Ovarian Cancer: Clinical Updates and Advances

Dear Colleagues,

The most unpredictable, the most heterogeneous, the most hidden, the quickest, the most aggressive, and lethal gynecological cancer—ovarian/peritoneal cancer.

We all dream of finding prevention methods, designing screening tools, being able to diagnose quicker, better predicting the outcome and safety of cytoreduction surgery, and composing more personalized systemic treatments to prevent our patients from recurrent disease followed by an unavoidable end. We wish we could combat ovarian cancer once and for all to keep our beloved grandmothers, mothers, sisters, and daughters with us.

Please share your valuable research on ovarian cancer with us and other professionals in this Special Issue of the Journal of Clinical Medicine. We hope that by combining our efforts, we can make the disease easier and provide better outcomes for our patients.

The suggested questions that need answers for this Special Issue are:

• Are there any ways to prevent ovarian cancer?
• Are there any possible screening methods for ovarian cancer for risk groups/all women?
• Ultrasound, laboratory markers, or both are methods of choice to diagnose ovarian cancer.
• Ultrasound, computed tomography, magnetic resonance, or other methods should be used to establish the radiologic staging and resectability of advanced ovarian cancer.
• How do we prepare our patients and maximize the safety of cytoreductive surgery?
• What are the limits of cytoreductive surgery?
• What is the role of cytoreductive surgery for recurrence?
• How can chemotherapy and targeted therapies be implemented in the primary treatment, maintenance therapy, and management of recurrent disease?
• Is it possible to implement targeted therapies designed according to the patient’s individual cancer tissue molecular analysis?

We would also welcome the results of translational research, especially the ones that have the power to exist and work in everyday clinical settings for our patients.

Dr. Maciej Stukan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ovarian cancer
• prehabilitation
• ultrasound
• radiologic staging
• cytoreductive surgery
• targeted treatment
• prevention
• screening